<DOC>
	<DOCNO>NCT01573767</DOCNO>
	<brief_summary>This Phase IIb , multi-centre , randomise , double-blind , parallel-group , placebo-controlled study child age 5-11 year persistent uncontrolled asthma . Subjects enter run-in period stop current asthma medication give open label fluticasone propionate ( FP ) 100mcg twice daily via DISKUS/ACCUHALER salbutamol/albuterol require use throughout run-in double-blind treatment period . At Visit 3 subject meet randomization eligibility criterion receive vilanterol ( 6.25mcg , 12.5mcg , 25mcg , ) placebo via Novel Dry Powder Inhaler ( NDPI ) daily 4 week addition open-label fluticasone propionate twice daily throughout treatment period . Primary endpoint consist change baseline clinic visit trough ( pre-bronchodilator pre-dose ) PEF end 28-day treatment period subject . Safety assessment include adverse event , oropharyngeal examination , clinical chemistry , 12-lead ECG , vital sign . Blood sample take subject pharmacokinetic analysis determine plasma concentration vilanterol specific time interval relative dose study drug .</brief_summary>
	<brief_title>Dose-ranging Study Vilanterol ( VI ) Inhalation Powder Children</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<criteria>Written inform consent least one parent/ legal guardian take part study . : Diagnosis asthma prebronchodilator PEF ≥50 % ≤90 % best postbronchodilator value Receiving stable asthma therapy short act betaagonist ( SABA ) plus ICS ( total daily dose FP 200mcg equivalent ) history lifethreatening asthma history asthma exacerbation asthma within 6 month prior screen . Culturedocumented suspected bacterial viral infection significant abnormality medical condition Present use tobacco product</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>11 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>